Turn on more accessible mode
Turn off more accessible mode
Skip Ribbon Commands
Skip to main content
Turn off Animations
Turn on Animations

Ongoing Research
 

  • Multiple Sclerosis
    • About Us
      • Mission & Vision
      • History
      • Virtual Tour
      • Faculty & Staff
      • Friends of MS at AUBMC
      • AUBMC Core Values
      • Why AUBMC?
      • Visiting AUBMC
    • Patient Care
      • MS Center Patient Care
      • MS Patient Educational Material
      • Patient Information
      • Patient Education
    • Divisions & Services
    • Research
      • Ongoing Research
      • Research Team
      • Khoury Lab Team
      • Publications
      • Research Newsletter
      • Joining MS Research Team
      • Volunteer in MS Research
    • Education
      • MS fellowship
      • Faculty of Medicine
      • GME
      • CME Office
      • RSO
Go
Quick Links
  • Facebook
  • Twitter
  • Help us by Donating
Find a doctor
Search by Name

Search by Specialty


Search by Keyword

Find a Doctor
NameSpecialtyContact Information
Contact Us:
http://www.aubmc.org.lb/clinical/ms/Pages/main/Ongoing-Research.aspx


Skip Navigation LinksAUBMC > Patient Care > Multiple Sclerosis

Ongoing Research

Page Content
​


1)     ENSEMBLE – MA30143: An Open-Label, Single-arm Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients with Early-Stage Relapsing-Remitting Multiple Sclerosis

Date: 2017-Ongoing

PI: Dr. Samia Khoury (previously Dr. Bassem Yamout)

 

2)     CONSONANCE-MN39159: An open-label, single-arm, 4-year study to evaluate the effectiveness and safety of ocrelizumab treatment in patients with progressive multiple sclerosis.

Date: 2019-Ongoing

PI: Dr. Samia Khoury (previously Dr. Bassem Yamout)

 

3)     COMB157G23101: A single-arm, prospective, multicentre, open-label study to evaluate ofatumumab treatment effectiveness and patient-reported outcomes in patients with relapsing multiple sclerosis transitioning from dimethyl fumarate or fingolimod therapy.

Date: 2021-Ongoing

PI: Dr. Samia Khoury

 

4)     WA40404 O'Hand: A phase III b multicenter, randomized, double-blind placebo-controlled study to evaluate the efficacy and safety of ocrelizumab in adults with primary progressive multiple sclerosis.

Date: 2022- Not initiated yet

PI: Dr. Samia Khoury

 

5)     CLOU064C12301: A randomized, double-blind, double-dummy, parallel-group study, comparing the efficacy and safety of remibrutinib versus teriflunomide in participants with relapsing multiple sclerosis, followed by extended treatment with open-label remibrutinib

PI: Dr. Samia Khoury

Date: Submitted to the IRB Sep 2022, still under review

 

6)     P3-IMU-838-RMS-01 (ENSURE-1): A Multi-Center, Randomized, Double-Blinded Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 versus Placebo in Adults with Relapsing Multiple Sclerosis (ENSURE-1)

Date: Not submitted to the IRB yet – still in negotiation phase

 

7)     SBS-2018-0498: Interacting with Nature using virtual reality: A pilot intervention to restore cognitive fatigue in patients with Multiple Sclerosis (MS)

Date: 2019-Ongoing

PI: Dr. Samia Khoury

 

8)     BIO-2017-0395: Longitudinal Effect of Vitamin D3 Replacement on Cognitive Performance and MRI Markers in Multiple Sclerosis Patients: A Single-Blind Randomized Clinical Trial

Date: 2018-Ongoing

PI: Dr. Samia Khoury

 

9)     SBS-2021-0430: The Arabic Validation of the Multiple Sclerosis Resiliency Scale on a Lebanese Sample 

Date: 2022- Ongoing

PI: Dr. Samia Khoury

 

10)  IM.SK1.01: Comprehensive Multiple Sclerosis Database.

Date: 2012 – Ongoing

PI: Dr. Samia Khoury

 

11)  IM.SK1.02: Immunological Pattern during Multiple Sclerosis Relapses and Response to Treatment.

Date: 2012 – Ongoing

PI: Dr. Samia Khoury

 

12)  IM.SK1.03: Exosomal microRNAs in Multiple Sclerosis: Reconciling Expression Signatures with Disease Relapse, Remission, and Response to Treatment.

Date: 2015 – Ongoing

PI: Dr. Samia Khoury

 
 

13)  IM.SK1.05: Cerebrospinal Fluid, Urinary and Plasma Biomarkers in Multiple Sclerosis.

Date: 2012 – Ongoing

PI: Dr. Samia Khoury

 

14)  IM.SK1.06: Development of immunological assays for Multiple Sclerosis.

Date: 2013 – Ongoing

PI: Dr. Samia Khoury

 

15)  IM.SK1.07: Correlation of retinal optical coherence tomography findings with cognitive function in patients with multiple sclerosis.

Date: 2014 – Ongoing

PI: Dr. Samia Khoury

 

16)  IM.SK1.08: EBV Infected B Lymphocyte Exosomes and Dendritic Cells:

Differential Cytokine Profile in Multiple Sclerosis.

Date: 2014 – Ongoing

PI: Dr. Samia Khoury

 

17)  IM.SK1.09: Clinical Usefulness of Visual, Somatosensory, and Brainstem Auditory Evoked Potentials for Monitoring of Disease Activity and Management in Multiple Sclerosis.

Date: 2015 – Ongoing

PI: Dr. Samia Khoury

​ 

18)  109MS311: A Multicenter Extension Study to Determine the Long-Term Safety and Efficacy of BG00012 in Pediatric Subjects With Relapsing-Remitting Multiple Sclerosis.

Date: 2016 – 2018 – Closed

PI: Dr. Bassem Yamout

 

19)  EFC11759: A two year, multicenter, randomized, double-blind, placebo-controlled, parallel group trial to evaluate efficacy, safety, tolerability, and pharmacokinetics of teriflunomide administered orally once daily in pediatric patients with relapsing forms of multiple sclerosis followed by an open-label extension.

Date: 2014 – 2022 Closed

PI: Dr. Bassem Yamout

 

20)  CFTY720D2404: The Multi-National Gilenya Pregnancy Exposure Registry in Multiple Sclerosis.

Date: 2013 – Ongoing

PI: Dr. Bassem Yamout

 

21)  IM.BY.10: Multiple Sclerosis Patient Registry:

Date: 2015 – Ongoing

Dr. Bassem Yamout

 

22)  IM.BY.11: Efficacy and Safety of Cyclophosphamide Treatment in Progressive Multiple Sclerosis: The Clinical Experience of the AUBMC Multiple Sclerosis Center in Lebanon.

Date: 2015 – Ongoing

Dr. Bassem Yamout

 

23)  MS200136_0035: A Multicenter, prospective, non-interventional study to assess Adherence to treatment for patients with Relapsing Multiple Sclerosis (RMS) who are prescribed subcutaneous (sc) interferon beta-1a.

Date: 2017 – 2021

Dr. Bassem Yamout

 

24)  TERIFR07918: Longitudinal assessment of clinical disability, cognition, quality of life, fatigue, brain magnetic resonance imaging measures, and optical coherence tomography findings in multiple sclerosis patients treated with AUBAGIO® (teriflunomide).

Date: 2016 – 2017

Dr. Bassem Yamout


25)  BICAMS: Brief International Cognitive Assessment for MS (BICAMS)-Arabic

Date: 2016 – closed

PI: Dr. Hala Darwish


26)  IM.SK1.04: Effect of Vitamin D Replacement on Immune Function and Cognition in MS Patients.

Date: 2012-2017

PI: Dr. Samia Khoury


27)   109MS202: : Open-Label, Multicenter, Multiple-Dose Study of the Effect of BG00012 on MRI Lesions and Pharmacokinetics in Pediatric Subjects With Relapsing-Remitting Multiple Sclerosis Aged 10 to 17 Years.

Date: 2015 – 2016

 

28)  CP-NU100-01.00: A phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of NU100 in Patients with Relapsing Forms of Multiple Sclerosis.

Date: 2012 – 2012

PI: Dr. Bassem Yamout


29)  28981: Double-blind extension of the study 27025 (REFLEX) to obtain long-term follow-up data in patients with clinically definite MS and patients with a first demyelinating event at high risk of converting to MS, treated with Rebif® New Formulation (REFLEXION).

Date: Ended

PI: Dr. Bassem Yamout

 

30)  EMR200559-006: A Phase III, Randomized, Double-Blind, Double-Dummy, Multicenter Trial Comparing the Efficacy and Safety of 2 Doses of Daily Oral ONO-4641 (0.05 mg and 0.1 mg) versus Interferon-β-1a 30 μg IM Weekly in Subjects with Relapsing-Remitting Multiple Sclerosis.

Date: 2014 – 2014

PI: Dr. Bassem Yamout

 

31)  EMR7008568-012: Prospective Observational Long-Term Safety Registry of Multiple Sclerosis Patients who have participated in Cladribine Clinical Trials (PREMIERE).

Date: 2015 – 2017

PI: Dr. Bassem Yamout


 

32)  IM.BY.07: Efficacy and safety of Fingolimod treatment in Multiple Sclerosis: The clinical experience of the AUBMC Multiple Sclerosis Center in Lebanon.

Date:  2014 - 2016 

PI: Dr. Bassem Yamout

 

33)  IM.BY.08: The Rate of Anti-JC Virus Antibody Seroconversion in the Middle East: A multi-Center Analysis.  

Date: 2014 – 2015

PI: Dr. Bassem Yamout

 

34)   IM.BY.09:  Incidence and Diagnostic Predictors of Mimickers of Multiple Sclerosis in a Specialized Referral Center in Lebanon.

Date: 2015 – 2017

PI: Dr. Bassem Yamout



35)  IM.BY.12: Safety and Efficacy of Natalizumab in Multiple Sclerosis: Real World Evidence in the Middle East

Date: 2016 – 2017

PI: Dr. Bassem Yamout

 

36)    Modulation of Th17 Differentiation and Survival by Vitamin D Via the Wnt/-catenin Pathway.

Date: 2015 – 2017

PI: Dr. Bassem Yamout
​
 

37)  The EBV Seropositivity, Vitamin D Level and Smoking Rate among Multiple Sclerosis patients compared to Healthy Individuals in Lebanon .

Date: 2012 - 2017  

PI: Dr. Bassem Yamout

 

 


Page Content 1
  • Webmail     A - Z     Careers     Disclaimer     Copyright